67.94
+0.11(+0.16%)
Currency In USD
| Previous Close | 67.83 |
| Open | 67.72 |
| Day High | 69.12 |
| Day Low | 67.45 |
| 52-Week High | 70.98 |
| 52-Week Low | 29.31 |
| Volume | 1.89M |
| Average Volume | 1.87M |
| Market Cap | 8.31B |
| PE | -10.78 |
| EPS | -6.3 |
| Moving Average 50 Days | 63.5 |
| Moving Average 200 Days | 49.58 |
| Change | 0.11 |
If you invested $1000 in Cytokinetics, Incorporated (CYTK) 10 years ago, it would be worth $10,080.12 as of February 21, 2026 at a share price of $67.94. Whereas If you bought $1000 worth of Cytokinetics, Incorporated (CYTK) shares 5 years ago, it would be worth $3,293.26 as of February 21, 2026 at a share price of $67.94.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
GlobeNewswire Inc.
Feb 17, 2026 12:30 PM GMT
European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Euro
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
GlobeNewswire Inc.
Feb 12, 2026 9:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time. Following the announcement,
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
GlobeNewswire Inc.
Feb 09, 2026 12:30 PM GMT
Grants Awarded to Two Patient Advocacy Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its eig